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Abstract
Background: Hybrid PET/optical imaging provides quantitative and complementary information for diagnosis of
tumors. Herein, we developed a 64Cu-labeled AlexaFluor 680-streptavidin ((AF)SAv)/biotin-based dimeric cyclic RGD
peptide (RGD2) for hybrid PET/optical imaging of integrin αVβ3 expression.
Methods: 64Cu-1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA)-(AF)SAv/biotin-PEG-RGD2 was
prepared by formation of a complex comprising DOTA-(AF)SAv and biotin-PEG-RGD2, followed by radiolabeling
with 64Cu. Receptor binding studies of DOTA-(AF)SAv/biotin-PEG-RGD2 were performed using U87MG cells and
125I-
RGDyK as the radioligand, and cellular uptake studies of 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2 were also performed.
MicroPET imaging followed by optical imaging of U87MG tumor-bearing mice was acquired after injection of the
hybrid probe, and region of interest (ROI) analysis of tumors was performed. Ex vivo PET/optical imaging and
biodistribution studies of the major tissues were performed after the in vivo imaging, and immunofluorescence
staining of the tumor tissue sections was carried out.
Results: 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2 was prepared in 52.1 ± 5.4 % radiochemical yield and with specific
activity of 1.0 ± 0.1 GBq/mg. Receptor binding studies showed that DOTA-(AF)SAv/biotin-PEG-RGD2 had higher binding
affinity for integrin αVβ3 than RGD2, reflecting a possible polyvalency effect. Moreover, the hybrid probe revealed
time-dependent uptake by U87MG cells. In a microPET/optical imaging study, the hybrid probe demonstrated high
accumulation in tumors; ROI analysis revealed 2.7 ± 0.2 % ID/g at 1 h and 4.7 ± 0.2 % ID/g at 21 h after injection, and
subsequently acquired optical images showed tumors with strong fluorescence intensity. Ex vivo PET/optical images of
the major tissues confirmed the in vivo imaging data, and biodistribution studies demonstrated high and specific
uptake in tumors (4.8 ± 0.1 % ID/g). Immunofluorescence staining showed the formation of new blood vessels in
tumor tissues, suggesting that the tumor uptake was due to specific binding of the hybrid probe to integrin αVβ3
expressed on tumor cells.
Conclusions: These results indicate that a 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2 is able to provide quantitative
information on hybrid PET/optical imaging of integrin αVβ3 expression.
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Background
Demand for hybrid imaging probes has been growing with
advances in hybrid imaging systems such as PET/CT,
SPECT/CT, and PET/MRI, and expansion of their clinical
uses [1]. PET provides sensitive and quantitative informa-
tion, and moreover, PET probes are easily translated for
clinical use compared with probes used for other modal-
ities [2]. However, PET has the disadvantage of low spatial
resolution. MRI offers the highest spatial resolution but
has low sensitivity [2]. Optical imaging has the advantages
of real-time imaging with high sensitivity and can poten-
tially be used in intraoperative image-guided surgery [2, 3].
However, it is mainly limited to small animal imaging due
to low depth penetration. Therefore, hybrid imaging, by
compensating for the drawbacks of single imaging modal-
ities, is more accurate and allows for earlier diagnosis of
diseases. This has spurred the development of hybrid
imaging probes containing diverse functionalities for appli-
cation in hybrid PET/optical, PET/MR, and other combi-
nations of imaging modalities.
To develop hybrid imaging probes, nanoparticles are
commonly used as platforms because of the ease of
addition of diverse functional groups including tumor-
targeting compounds. For tumor angiogenesis targeting,
cyclic Arg-Gly-Asp (RGD) peptides, selective antagonists
of integrin αVβ3, have been radiolabeled with various radio-
isotopes. The most well-characterized ligand, 18F-labeled
galacto-RGD peptide, has shown promise for tumor im-
aging of melanoma M21 tumor-bearing mice and diagnosis
of cancer patients [4, 5]. With its longer half-life, 64Cu-la-
beled RGD peptide showed prolonged tumor uptake in
MDA-MB-435 tumor-bearing mice [6]. In addition, PEGy-
lation of RGD peptides improved in vivo pharmacokinetics;
64Cu-labeled PEGylated RGD peptide accumulated in tu-
mors at early time points and rapidly washed out from the
blood of U87MG tumor-bearing mice compared with
64Cu-labeled RGD peptide [7, 8]. Multimeric RGD pep-
tides, such as 64Cu-labeled RGD dimer and tetramer, were
shown to possess not only higher integrin binding affinity
compared with the corresponding monomer but also pro-
longed tumor retention and increased renal excretion in
tumor-bearing mice, which were possibly attributed to a
polyvalency effect [9, 10]. Other dimeric RGD peptides, la-
beled with 18F, 68Ga, and 99mTc, have also been shown to
have superior in vivo properties than their corresponding
monomers [11–14].
Nanoparticles such as liposomes, quantum dots, gold
nanoparticles, carbon nanotubes, and others have been
conjugated with RGD peptides and utilized for hybrid im-
aging or improved tumor targeting. 111In-DTPA-labeled
liposomes conjugated with RGD peptide were designed
for hybrid SPECT/MR imaging of integrin αVβ3. Although
111In-labeled liposomes exhibited low tumor uptake in
U87MG tumor-bearing mice, Gd-labeled liposomes were
taken up by the tumors of both U87MG and M21 tumor-
bearing mice, based on R1 values [15]. 64Cu-labeled
quantum dots (Qdots) modified with RGD peptides were
developed for PET and near-infrared fluorescence (NIRF)
imaging, and the tumor vasculature was visualized by both
PET and ex vivo NIRF imaging [16]. In another study,
RGD peptides and DOTA were conjugated to polyaspartic
acid-coated iron oxide nanoparticles, which were then
labeled with 64Cu. Hybrid PET/MR imaging of the parti-
cles in U87MG tumor-bearing mice showed integrin αVβ3
expression in the tumor [17]. 125I-labeled RGD-PEG-gold
nanoparticles were prepared by conjugating PEG to the
gold particles and RGD peptide to PEG, and then finally
radiolabeling the particles with 125I. RGD-PEG-gold nano-
particles exhibited much higher binding affinity for integrin
αVβ3 on U87MG cells than free RGDyC peptide. SPECT/
CT images of U87MG tumor-bearing mice showed fast
tumor uptake of the gold particles [18]. Single-walled car-
bon nanotubes have also been used as a platform for tumor
angiogenesis imaging; carbon nanotubes coated with RGD-
and DOTA-conjugated PEG-phospholipids were labeled
with 64Cu, and then the resulting nanotubes had a high
tumor uptake in U87MG tumor-bearing mice. Ex vivo Ra-
man spectroscopy data of the major tissues confirmed the
microPET imaging data [19].
Previously, we and others showed that a streptavidin
(SAv) and biotin complex can serve as a useful platform
for the development of hybrid imaging probes due to
the strong interaction between SAv and biotin, with a
dissociation constant of approximately 10−14 M [20]. Ex-
amples of these probes include 99mTc-HYNIC-labeled
quantum dots (Qdots)-SAv/biotin-PEG-EGF, SAv/three
biotinylated 111In-DOTA, Cy5.5 and anti-Her2 antibody,
and 64Cu-DOTA-(AF)SAv/biotin-PEG-VEGF121 [21–23].
Unlike most nanoparticles, antibody-conjugated SAv and
90Y-DOTA-biotin have been used clinically for pretargeted
radioimmunotherapy, which was shown to be safe [24].
In this study, we extended application of the SAv/biotin
platform to the development of an E[cyclic(RGDyK)]2
(RGD2)-based hybrid imaging probe for tumor angiogenesis
imaging. Therefore, 64Cu-DOTA-(AlexaFluor680; AF)SAv/
biotin-PEG-RGD2 was prepared and evaluated for hybrid
PET/optical imaging of integrin αVβ3 receptor expression
in U87MG tumor-bearing mice.
Methods
Materials and equipment
RGD2 was purchased from Peptide International (Louisville,
KY, USA), biotin-PEG(3400)-NHS ester was from Nanocs
(New York, NY, USA), (AF)SAv was from Life Technologies
(Carlsbad, CA, USA), and DOTA-NHS ester was from
Macrocyclics (Dallas, TX, USA). 64CuCl2 was kindly
provided by KIRAMS (Seoul, Korea). PD-10 columns
were purchased from Amersham Biosciences
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(Piscataway, NJ, USA), Amicon filters were from Milli-
pore (Billerica, MA, USA), and spin columns were from
Thermo Scientific (Rockford, IL, USA). Chelex 100 resin
(50–100 mesh) and other chemicals were purchased from
Sigma-Aldrich (St. Louis, MO, USA), and BCA protein
assay kits were from Pierce (Rockford, IL, USA). All buffers
used for synthesis and radiolabeling were pretreated with
Chelex 100 resin to ensure that they were metal-free.
Matrix-assisted laser desorption ionization time of flight
(MALDI-TOF) mass spectrometry was performed on a
Voyager-DETM STR Biospectrometry Workstation (Ap-
plied Biosystems, Foster City, CA, USA). Purification and
analysis of products were performed by HPLC (Thermo
Scientific, Waltham, MA, USA), and eluates were moni-
tored using a UV detector (218 nm).
Radioactivity was measured using a dose calibrator (Bio-
dex Medical Systems, Shirley, NY, USA), and tissue radio-
activity was counted using an automatic gamma counter
(PerkinElmer, Waltham, MA, USA). MicroPET and optical
images were acquired at the Center for Molecular and
Cellular Imaging, Samsung Biomedical Research Institute
(SBRI, Seoul, Korea) using an Inveon microPET/CT scan-
ner (Siemens Medical Solutions, Malvern, PA, USA) and a
Xenogen IVIS Spectrum (Caliper Life Sciences, Hopkinton,
MA, USA), respectively.
Preparation of DOTA-(AF)SAv
(AF)SAv (1.3 mg) and 20 equivalents of DOTA-NHS ester
(400 μg, 481.9 nmol) were dissolved in 800 μL of 0.1 M so-
dium carbonate buffer (pH 8.5), which was then stirred at
room temperature for 18 h in the dark. At the end of the
reaction, the reaction mixture was purified using a PD-10
column, concentrated using an Amicon filter (cut-off:
10 kDa), and then lyophilized. DOTA-(AF)SAv was ob-
tained at 97.3 % yield, quantified using a BCA protein assay
kit, and then analyzed by MALDI-TOF mass spectrometry.
Preparation of biotin-PEG-RGD2
RGD2 (1.7 mg, 1.3 μmol) and biotin-PEG(3400)-NHS ester
(2.4 mg, 0.6 μmol) were dissolved in 500 μL of 0.1 M
sodium carbonate buffer (pH 8.5), which was then stirred
at room temperature for 19 h. At the end of the reaction,
the reaction mixture was purified by HPLC using a C18
column (YMC, 5 μm, 10 × 250 mm) with sequential pro-
grams using a mixture of 0.1 % trifluoroacetic acid (TFA) in
water and CH3CN. The first isocratic program was a 90:10
mixture over 10 min, and the second gradient program was
from a 90:10 mixture to a 35:65 mixture over 30 min. The
flow rate was 3 mL/min. After lyophilization, biotin-PEG-
RGD2 was analyzed by MALDI-TOF mass spectrometry.
Preparation of 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2
Biotin-PEG-RGD2 (91.2 μg, 18.2 nmol) dissolved in acet-
ate buffer (pH 6) was added to DOTA-(AF)SAv (201.9 μg,
3.6 nmol) in the same buffer. The reaction mixture (total
volume of 200 μL) was stirred at room temperature for
1 h, and then incubated with 64CuCl2 (377 MBq) at 40 °C
for 30 min with constant shaking. Unreacted 64CuCl2 and
biotin-PEG-RGD2 in the reaction mixture were removed
by centrifugation using a spin column (molecular weight
(mw) cut-off 7 kDa).
In a separate experiment, an aliquot of DOTA-(AF)SAv/
biotin-PEG-RGD2 was purified using a spin column (cut-
off 7 kDa) and its purity was determined by HPLC using a
Superdex™ 75 GL column (10 × 300 mm, GE Healthcare
Life Sciences, Marlborough, MA, USA) and 0.01 M phos-
phate buffer as the eluent at a flow rate of 0.7 mL/min.
Serum stability
64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2 (98.4 MBq) in
0.01 M PBS (pH 7.4) was added to 50 % fetal bovine serum
(FBS; Gibco, Brooklyn, NY, USA) and incubated at 37 °C
for 0, 1, 3, 16, and 24 h. At the indicated time points, each
sample was loaded onto a PD-10 column, and fractions
were eluted using PBS (pH 7.4) and counted using a dose
calibrator.
Cell integrin receptor binding
The integrin αVβ3 receptor binding study was performed
using a previously reported procedure with a slight modifi-
cation [25]. 125I-RGDyK was used as the radioligand and
prepared immediately before use. U87MG cells (2 × 106
cells/100 μL) cultured in minimum essential media (MEM;
Gibco) were re-suspended in binding buffer (20 mM Tris–
HCl buffer with 150 mM NaCl, 2 mM CaCl2, 1 mMMgCl2,
1 mM MnCl2, and 0.1 % bovine serum albumin (BSA); pH
7.4). 125I-RGDyK (2.7 kBq/80 μL of binding buffer) was
added to tubes containing U87MG cells in the presence
of different concentrations (0.1, 1, 10, 102, 103, 104, and
105 nM; 20 μL) of either DOTA-(AF)SAv/biotin-PEG-
RGD2 or RGD2 at room temperature for 1 h. After incu-
bation, the cells were washed three times with PBS for
5 min, re-suspended with PBS (1 mL), and then counted
using a gamma counter. All experiments were performed
in triplicate. IC50 values were determined using GraphPad
Prism software 5.
Cellular uptake
U87MG cells were cultured in MEM supplemented with
10 % FBS, streptomycin (100 μg/mL), and penicillin (100
units/mL). Cells were maintained at 37 °C in a humidified
5 % CO2 incubator. U87MG cells were seeded in 12-well
plates at 5 × 105 cells/well and cultured for 2 days. 64Cu-
DOTA-(AF)SAv/biotin-PEG-RGD2 (111 kBq/2 μL) was
added to each well, and the cells in a total volume of
0.5 mL were incubated at 37 °C for 1, 2, 16, and 21 h.
After incubation, the cells were washed three times with
PBS. Cell lysis was then carried out using 0.1 N NaOH,
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and the resulting lysate was counted using a gamma coun-
ter. For the blocking study, cells were incubated with the
hybrid probe in the presence of RGD2 (10 μM) at 37 °C
for 21 h and then treated as described above. All experi-
ments were performed in triplicate.
Ethics statement
This study was reviewed and approved by the Institu-
tional Animal Care and Use Committee of SBRI. SBRI is
an Association for Assessment and Accreditation of La-
boratory Animal Care International accredited facility
and abide by the Institute of Laboratory Animal Re-
sources guide.
In vivo microPET/optical imaging
U87MG tumor-bearing mice were prepared by subcuta-
neously inoculating U87MG cells (5 × 106) into the right
hind legs of 5-week-old BALB/c nude mice (male).
When tumor size reached 407.4 ± 58.6 mm3 at 3 weeks
after inoculation, the 64Cu-DOTA-(AF)SAv/biotin-PEG-
RGD2 (6.9 ± 0.3 MBq/200 μL) was injected intravenously
without (n = 3) or with RGD2 (20 mg/kg, n = 3) through
the tail vein. MicroPET static images were acquired for
10 min at 1, 2, 16, and 21 h after injection. Immediately
after microPET imaging, optical images of the mice were
acquired (excitation: 675 nm, emission 720 nm) for 1 s.
The images obtained were reconstructed using three-
dimensional ordered subset expectation maximization and
then processed using Siemens Inveon Research Workplace
4.2. Regions of interest (ROIs) were drawn over tumors in
the right legs, and the average signal levels in the ROIs
were measured. Data are expressed as percent injected
dose per gram of tissue (% ID/g). ROIs of optical images
were drawn over tumors, and signal levels were measured
using Living Image 3.2 software. These data are presented
as photons per second per square centimeter per steradian
(photons/s/cm2/sr).
Ex vivo imaging and biodistribution studies
At the end of the in vivo microPET/optical imaging study,
mice were sacrificed, and major tissues (heart, lungs, liver,
spleen, kidneys, intestines, muscle, and tumor) were sepa-
rated immediately and subjected to ex vivo imaging (micro-
PET, 10-min static scan; optical imaging, 1-s exposure).
ROIs of ex vivo images were drawn around each tissue, and
the average signal level in the ROI was measured. For the
biodistribution study, the tissues of interest and blood were
then weighed and counted, and data are expressed as per-
cent injected dose per gram of tissue.
Immunofluorescence staining
Tumor tissues obtained after in vivo imaging were fixed in
4 % paraformaldehyde overnight. Specimens were then
dehydrated in graded ethanol, embedded in paraffin, and
sectioned at 5 μm on a Reichert microtome. The sections
were blocked with 1 % BSA in PBS for 30 min and then
incubated with goat anti-β3 (1:100; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) and rabbit anti-VEGFR2 anti-
bodies (1:100; Santa Cruz Biotechnology) overnight at 4 °C.
Subsequently, sections were stained with FITC-labeled
anti-goat and rhodamine-labeled anti-rabbit antibodies
(1:200; Santa Cruz Biotechnology). Hoechst 33342
(1 μg/mL; Cell Signaling Technology, Danvers, MA,
USA) was used to stain the cell nuclei of tumor tis-
sues. Stained tissue sections were examined under a
microscope (×200; Nikon Eclipse 80i).
Statistical analysis
Data were analyzed with unpaired, two-tailed Student’s t
tests. Differences at the 95 % confidence level (P < 0.05)
were considered statistically significant.
Results
Preparation of DOTA-(AF)SAv and biotin-PEG-RGD2
DOTA-(AF)SAv prepared from (AF)SAv and DOTA-NHS
ester was readily purified using a size-exclusion column.
MALDI-TOF mass spectrometric analysis indicated that
the average number of DOTA molecules conjugated to
(AF)SAv was 3.8 ± 0.6. In contrast, to prepare biotin-PEG-
RGD2, excess amounts (2 equivalents) of RGD2 were used
to consume as much biotin-PEG-NHS ester as possible, as
this NHS ester eluted close to biotin-PEG-RGD2 on
HPLC. The resulting biotin-PEG-RGD2 was purified by
HPLC, but not using a size-exclusion column because of
its similarity in molecular weight to the biotin-PEG-NHS
ester. Biotin-PEG-RGD2 was obtained at 87.1 ± 8.1 % yield
and identified by MALDI-TOF mass spectrometry: (m/z)
[M +H]+ calcd. 5023.77, C225H413N22O98S; found 5024.57.
Preparation of 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2
Purity of a DOTA-(AF)SAv/biotin-PEG-RGD2 complex
after spin column purification was confirmed by HPLC
using a Superdex™ 75 GL column (Fig. 1a, b). To reduce
the requirement for two-step purification comprising
DOTA-(AF)SAv/biotin-PEG-RGD2 purification using a
spin column and 64Cu-DOTA-(AF)SAv/biotin-PEG-
RGD2 purification using a PD-10 column, the hybrid
probe was prepared in a two-step reaction and finally
purified; DOTA-(AF)SAv and biotin-PEG-RGD2 were
mixed at a ratio of 1 to 5, which was then labeled
with 64Cu, and finally the hybrid probe was purified
using a spin column. Non-decay-corrected radiochem-
ical yield of the 64Cu-DOTA-(AF)SAv/biotin-PEG-
RGD2 was 52.1 ± 5.4 % and its specific activity was
1.0 ± 0.1 GBq/mg.
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Serum stability
In vitro serum stability of the 64Cu-DOTA-(AF)SAv/bio-
tin-PEG-RGD2 was measured by incubating the hybrid
probe in 50 % serum for 24 h. The results demonstrated
that 64Cu remained stable on the hybrid probe after the
24-h incubation, showing 96.4 % radioactivity at 1 h,
97.8 % at 3 h, 98.1 % at 16 h, and 97.6 % at 24 h relative
to a value of 100 % radioactivity at 0 h (Fig. 2).
Cell integrin receptor binding
Receptor binding affinity measurements of DOTA-
(AF)SAv/biotin-PEG-RGD2 and RGD2 were performed
using U87MG cells and 125I-RGDyK as the radioligand.
IC50 values of DOTA-(AF)SAv/biotin-PEG-RGD2 and
RGD2 were 12.1 ± 4.2 nM and 37.5 ± 18.3 nM, respect-
ively, indicating that the former had higher binding af-
finity for integrin αVβ3 than RGD2 (Fig. 3).
Cellular uptake
Cellular uptake of the 64Cu-DOTA-(AF)SAv/biotin-
PEG-RGD2 increased in a time-dependent manner from
100.0 % at 1 h to 298.5 % at 21 h (Fig. 4a). In the block-
ing study, the cellular uptake decreased to 72.2 % in the
presence of RGD2 (10 μM), indicating specific binding
of the hybrid probe to the integrin αVβ3 expressed on
tumor cells (Fig. 4b).
MicroPET/optical imaging
In vivo microPET and optical imaging of U87MG tumor-
bearing mice showed high uptake of the 64Cu-DOTA-
(AF)SAv/biotin-PEG-RGD2 in the liver, spleen, and tumor
(Fig. 5a). ROI values of tumor tissues were 2.7 ± 0.2 % ID/g
at 1 h, 2.8 ± 0.2 % ID/g at 2 h, 4.4 ± 0.2 % ID/g at 16 h, and
4.7 ± 0.2 % ID/g at 21 h (Fig. 5e). In the blocking study,
tumor uptake was inhibited by 30.3 % in the presence of
RGD2 (20 mg/kg) at 16 h after injection (Fig. 5b, e). In op-
tical images, strong fluorescence signals were detected in
the liver and tumor, which was a similar uptake pattern to
that observed in the PET images (Fig. 5c, d). ROI values of
tumor tissues revealed fluorescence signals of (3.7 ± 0.2) ×
108 photons/s/cm2/sr at 1 h, (3.9 ± 0.3) × 108 photons/s/
cm2/sr at 2 h, (6.0 ± 0.2) × 108 photons/s/cm2/sr at 16 h,
and (6.7 ± 0.3) × 108 photons/s/cm2/sr at 21 h. In the pres-
ence of RGD2, signal intensity decreased to 4.9 ± 0.2 × 10
8
photons/s/cm2/sr at 21 h (Fig. 5f).
Ex vivo imaging and biodistribution studies
Ex vivo PET and optical imaging carried out immediately
after in vivo imaging demonstrated high signal intensity in
the liver, spleen, and tumor, consistent with the in vivo im-
aging data (Fig. 6a–d). The ROI values of ex vivo PET im-
ages were 25.4 ± 3.1 % ID/g in the liver, 22.4 ± 1.9 % ID/g
Fig. 1 Size-exclusion HPLC profiles of DOTA-(AF)SAv/biotin-PEG-RGD2
before (a) and after purification (b) using a spin column
Fig. 2 Serum stability of the 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2.
Stability was measured using PD-10 columns, and percent radioactivity
was determined relative to the value at 0 h (100 %)
Fig. 3 Integrin αVβ3 receptor binding of the hybrid probe. 125I-RGDyK
was used as the radioligand. IC50 values of DOTA-(AF)SAv/biotin-PEG-
RGD2 (closed circles) and RGD2 (open circles) were 12.1 ± 4.2 nM and
37.5 ± 18.3 nM, respectively (n = 3)
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in the spleen, 5.0 ± 0.1 % ID/g in the tumor, and 0.9 ± 0.1 %
ID/g in the muscle. In the blocking study, the tumor ROI
value was inhibited by 34.9 %. Similarly, ROI analysis of ex
vivo optical images showed (16.0 ± 1.0) × 107 photons/s/
cm2/sr in the liver, (4.2 ± 0.2) × 107 photons/s/cm2/sr in the
spleen, and (3.0 ± 0.2) × 107 photons/s/cm2/sr in the
tumor (Fig. 6c). In the blocking group, the fluorescence
intensity of the hybrid probe in the tumor decreased to
(2.4 ± 0.1) × 107 photons/s/cm2/sr (Fig. 6d).
The biodistribution study performed after ex vivo im-
aging confirmed the in vivo and ex vivo microPET/optical
imaging data; 30.6 ± 1.7 % ID/g in the liver, 26.2 ± 1.1 % ID/
g in the spleen, and 4.8 ± 0.1 % ID/g in the tumor (Fig. 7).
In the blocking study using RGD2, tumor uptake of the hy-
brid probe was inhibited by 32.3 %, whereas there was no
significant uptake inhibition in the blood or in other organs
(Fig. 7). Tumor-to-muscle and tumor-to-blood uptake ra-
tios obtained with the hybrid probe were 5.0 and 2.3, re-
spectively, whereas ratios in the blocking group were 3.7
and 1.6, respectively, indicating the high specificity of the
64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2 for integrin αVβ3.
Immunofluorescence staining
Immunofluorescence staining of tumor tissue sections of
mice injected with the 64Cu-DOTA-(AF)SAv/biotin-PEG-
RGD2 confirmed expression of β3 (green) and VEGFR2
(red), and the fluorescence signals from β3 overlapped with
those of VEGFR2 (Fig. 8). This result indicates formation
of new blood vessels and tumor angiogenesis in the tumor
tissues.
Discussion
DOTA-(AF)SAv and biotin-PEG-RGD2 were prepared via
amide bond formation under basic conditions (pH 8.5). Dif-
ferent methods were applied to purify these two molecules
due to differences in their molecular weights from reac-
tants; DOTA-(AF)SAv was purified using a PD-10 column,
in which the unconjugated DOTA was easily removed be-
cause of its low molecular weight (mw 501.49), whereas
biotin-PEG-RGD2 was purified using a centrifugal filter to
remove unreacted RGD2 peptide (mw 1350.43), followed by
a reverse-phase HPLC column because of the small differ-
ence in molecular weight between biotin-PEG-NHS ester
(mw 3790.48) and biotin-PEG-RGD2 (mw 5025.83). As a
result, there were no molecular ion peaks corresponding
to both biotin-PEG-NHS ester and RGD2 detected on
MALDI-TOF mass spectrometry, except for the molecular
ion peak of biotin-PEG-RGD2. The key to preparing a
SAv/biotin complex is to remove unbound biotin-PEG-
RGD2 after the complex formation. In this study, we used
a spin column (mw cut-off 7 kDa) to rapidly remove mol-
ecules with a molecular weight less than 7 kDa from the
64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2.
SAv/biotin complexes have previously been used to de-
velop imaging probes; IRDye800-SAv/biotin-Avi-VEGF121
and 64Cu-DOTA-(AF)SAv/biotin-PEG-VEGF121 were shown
to have potential for NIRF and PET/optical imaging of
VEGF receptor expression, respectively [23, 26]. More-
over, SAv bound to biotinylated 111In-DOTA, Cy5.5, and
anti-Her2 antibody showed high tumor uptake in
SUMI190 tumor-bearing mice [22]. In our study, RGD2
was conjugated to biotin via PEG to improve its in vivo
properties and provide flexibility, while 64Cu-DOTA was
directly conjugated to SAv(AF). This imaging probe design
may be suitable for hybrid imaging of tumor angiogenesis,
because RGD2 can be used for αVβ3 receptor binding
while the radioisotope and fluorescent dye can be used for
PET and optical imaging, respectively. A long PEG chain
(mw 3400) was used to allow RGD2 to gain access to the
binding site of the integrin receptor, while the radioisotope
and fluorescent dye were conjugated directly to SAv not to
interfere with binding of RGD2 to the integrin receptor.
Furthermore, the hybrid probe was stable for 24 h based on
an in vitro serum stability study (Fig. 2). In comparison with
in vivo PET imaging of 64Cu-DOTA-(AF)SAv without bio-
tin molecules [23], the 64Cu-DOTA-(AF)SAv/biotin-PEG-
Fig. 4 a U87MG cellular uptake of the 64Cu-DOTA-(AF)SAv/biotin-PEG-
RGD2 as a function of time. b Cellular uptake of the hybrid probe at 21 h
into the incubation (black) and after co-incubation with 10 μM of RGD2
(white). Data are means ± SDs from triplicate experiments. **P< 0.01
and ***P< 0.001
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RGD2 showed higher tumor uptake that increased in a
time-dependent manner, reflecting its long-term stability in
vivo.
To evaluate the receptor binding affinity of the probe,
U87MG cells, which are known to express high levels of in-
tegrin αVβ3 [27], were incubated with
125I-RGDyK in the
presence of different concentrations of DOTA-(AF)SAv/
biotin-PEG-RGD2 or RGD2. IC50 value of DOTA-(AF)SAv/
biotin-PEG-RGD2 was 3.1-fold higher than that of RGD2
(Fig. 3). Diverse dimeric and multimeric RGD peptides have
been shown to have higher in vitro receptor binding
affinity and tumor uptake than monomeric RGD pep-
tides [12, 28]. In this study, four equivalents of the
RGD2 peptide were possibly bound to one molecule of
SAv because of its tetrameric structure, which might have
contributed to the higher binding affinity of the 64Cu-
DOTA-(AF)SAv/biotin-PEG-RGD2 than the dimeric RGD
peptide probably due to a polyvalency effect [9, 10]. Cellu-
lar uptake study exhibited that the hybrid probe was taken
up by U87MG cells in a time-dependent manner, and that
its levels increased 3.0-fold over a 21-h incubation (Fig. 4a).
Cellular uptake was inhibited significantly by RGD2,
Fig. 6 Ex vivo microPET (a control; b blocking) and optical images (c control; d blocking) of major tissues obtained after in vivo imaging (21 h)
Fig. 5 a MicroPET images of the 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2 in U87MG tumor-bearing mice at 1, 2, 16, and 21 h after injection and (b) after
co-injection with RGD2 (20 mg/kg). c Optical images at the same time points and (d) after co-injection with RGD2 (20 mg/kg). Arrows indicate
tumors. e ROI analysis of radioactivity uptake in tumors obtained from microPET images (a, b): control (black) and blocking (white) groups. f ROI analysis
of fluorescence intensity in tumors obtained from optical images (c, d): control (black) and blocking (white) groups. Values represent mean % ID/g and
error bars indicate SD (n = 3). **P < 0.01, ***P < 0.001
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indicating specificity of the probe to the integrin αVβ3 re-
ceptor (Fig. 4b).
In vivo microPET and optical imaging results of 64Cu-
DOTA-(AF)SAv/biotin-PEG-RGD2 demonstrated incre-
mental tumor uptake over time. ROI values of tumor
uptake obtained from microPET images increased 1.7-fold
over 21 h (Fig. 5a). A similar pattern of tumor uptake was
observed in optical images, with uptake increasing 1.8-fold
over the same period of time (Fig. 5c). Biodistribution data
of this hybrid probe demonstrated higher tumor uptake
(4.8 ± 0.1 % ID/g at 21 h after injection) than that of 64Cu-
DOTA-E[(RGDfK)]2 in U87MG tumor-bearing mice (<4 %
ID/g at 4 h after injection) [9], although 64Cu-DOTA-
E[(RGDyK)]2 showed better in vivo kinetics than the D-Phe
derivative in MDA-MB-435 tumor-bearing mice [10].
Furthermore, the tumor uptake pattern of 64Cu-DOTA-
(AF)SAv/biotin-PEG-RGD2 was similar to that reported
for other RGD-conjugated nanoparticles. 64Cu-DOTA-
QDot-RGD showed relatively low tumor uptake at 1 h
after injection (less than 1 % ID/g), which then increased
to 4.3 ± 0.5 % ID/g at 25 h after injection based on ROI
analysis of microPET images [16]. Higher tumor uptake
was detected in 64Cu-labeled RGD-conjugated iron oxide
nanoparticles, which were avidly taken up by U87MG tu-
mors of mice (7.9 ± 0.8 % ID/g at 1 h after injection) and
increased to 9.8 ± 3.2 % ID/g at 21 h after injection [17].
Another study showed that 64Cu-DOTA- and RGD-
conjugated single-walled carbon nanotubes exhibited sig-
nificantly high tumor uptake of 10–15 % ID/g at 24 h after
injection compared to 3–4 % ID/g uptake of RGD-free
nanotubes [19]. The presence of SAv in the hybrid probe
may affect tumor uptake, because 111In-labeled SAv was
reported to accumulate in tumors in LS174T tumor mice
(4.5 ± 0.2 % ID/g at 5 h after injection) [29]. In our previ-
ous study, however, 64Cu-DOTA-(AF)SAv without biotin
molecules showed low tumor uptake (1.6 ± 0.1 % ID/g at
22 h) [23]. Therefore, tumor uptake of the 64Cu-DOTA-
(AF)SAv/biotin-PEG-RGD2 was likely due to the probe
itself.
The hybrid probe showed high uptake in the liver and
spleen compared with that of 64Cu-DOTA-E[(RGDfK)]2
[9]. This high uptake in the reticuloendothelial system re-
sulted from the presence of the relatively large molecule,
SAv, as shown by high liver uptake of 64Cu-DOTA-(AF)SAv
(15.7 ± 0.57 % ID/g at 22 h) [23]. A similar uptake pattern
was detected in microPET images of U87MG tumor-
Fig. 7 Biodistribution data of the 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2 in U87MG tumor-bearing mice at 21 h after injection (black) and after co-injection
with RGD2 (white). Inset is an enlarged graph showing tumor uptake of the control (black) and blocking (white) groups. I indicates intestine. Values represent
mean % ID/g and error bars indicate SD (n= 3). ***P< 0.001
Fig. 8 Immunofluorescence staining of U87MG tumor tissue sections obtained after microPET/optical imaging. Cell nuclei are shown as blue dots.
Magnification ×200. Arrows indicate overlay areas
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bearing mice injected with 64Cu-DOTA-QDot-RGD; liver
uptake was higher than 40 % ID/g up to 25 h after injec-
tion based on ROI analysis [16]. 64Cu-labeled RGD-
conjugated iron oxide nanoparticles also showed high liver
uptake (31.1 ± 2.5 % ID/g at 1 h and 11.7 ± 1.2 % ID/g at
21 h after injection), probably due to the relatively large
size of the particles [17]. Similarly, high liver uptake
(17~30 % ID/g at 24 h) was also detected in mice injected
with 64Cu-labeled single-walled carbon nanotubes coated
with phospholipid-PEG chains conjugated to the RGD
peptide [19]. The longer the PEG chain, the lower the liver
uptake and the higher the tumor uptake of nanotubes
[19]. Therefore, use of longer PEG arms may improve the
in vivo properties of the 64Cu-DOTA-(AF)SAv/biotin-PEG-
RGD2 by reducing liver uptake. Optical images confirmed
the microPET imaging data for the hybrid probe and
showed high fluorescence intensity in tumors that increased
over time (Fig. 5c, d). While the 64Cu-DOTA-(AF)SAv/bio-
tin-PEG-RGD2 was taken up by the liver and spleen based
on PET imaging, this was not clear from optical images due
to the presence of the skeleton and the depth penetration
limitations of optical imaging. However, ex vivo optical im-
ages revealed that the hybrid probe was taken up by the
liver, spleen, and tumor (Fig. 6c, d).
Immunofluorescence staining of tumor tissue sections
obtained after microPET/optical imaging demonstrated
that β3 receptors were highly expressed on endothelial
cells (VEGFR2) of blood vessels (Fig. 8). This result sug-
gests that tumor uptake of the hybrid probe was attrib-
utable to its binding to integrin αVβ3.
Our study showed that both microPET and optical im-
aging data of 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2 in
U87MG tumor-bearing mice were in good agreement
for monitoring integrin αVβ3 expression. This hybrid
probe provided real-time detection of tumor as well as
quantitative information on tumor and major organs
with high specificity and sensitivity. In addition, this hy-
brid probe may have advantages, because hybrid PET/
optical probes may allow for preoperative detection, in-
traoperative image-guided surgery, and postoperative
evaluation of tumors.
Conclusions
We prepared a 64Cu-DOTA-(AF)SAv/biotin-PEG-RGD2
efficiently using a SAv/biotin complex as a platform. As
shown by a receptor binding study, DOTA-(AF)SAv/bio-
tin-PEG-RGD2 exhibited higher binding affinity for the in-
tegrin αVβ3 than RGD2 peptide, which we attributed to a
possible polyvalency effect by four flexible biotin-PEG-
RGD2 arms complexed with one SAv core. PET/optical
images of U87MG tumor-bearing mice indicated that the
hybrid probe accumulated in tumor with prolonged reten-
tion over 21 h. These results demonstrate that 64Cu-
DOTA-(AF)SAv/biotin-PEG-RGD2 provides specific and
sensitive hybrid PET/optical images for monitoring integ-
rin αVβ3 expression, and that a SAv/biotin complex is a
useful platform for developing hybrid imaging probes.
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